Ace Therapeutics recently launched in vivo efficacy testing services for IBD drug candidates. Ace Therapeutics, a preclinical ...

Researchers at the University of Plymouth are leading an innovative initiative to advance the study of meningiomas in NF2-related schwannomatosis (NF2-SWN). Meningiomas, often linked to the loss of ...

A new precision medicine initiative is doing a bit of pharmaceutical matchmaking to see if preclinical evidence for cancer drug combos holds up beyond the lab. The National Institutes of Health (NIH) ...

Experts predict a test measuring p-tau217 in blood plasma may become a standard screening tool for Alzheimer’s disease in asymptomatic patients.

'OPENING THE DOOR': FDA's Joseph Contrera claims the new testing guidelines will encourage innovation. The Food and Drug Administration (FDA) is considering a plan to revise a 25-year staple of ...

MED Institute, a leader in pre-clinical and clinical medical product development services, is proud to announce a strategic collaboration with Sus Clinicals, a pioneering provider of genetic-modified ...

Plasma phosphorylated (p)-tau217 testing can help identify preclinical Alzheimer's disease (AD), which could aid clinical trial recruitment. Recruiting preclinical AD participants for clinical ...

Approximately 75% of anticancer drugs must be tested against paediatric cancer. Drug developers can now use a database of patient-derived tumour models to screen their products for paediatric cancer ...

Modeling and simulation will be a key component for shift to non-animal methodologies Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy ...

The Baylor/Rice Genome Editing Testing Center (GETC) offers researchers in vivo evaluation of genome editing activity, biodistribution and efficacy in mouse models as a fee-for-service. Our center ...

The US Food and Drug Administration (FDA) has taken another step away from animal testing – this time through draft guidance encouraging the reduction or cessation of non-human primate toxicity ...

For decades, researchers have sought a fast track to drug discovery. Yet the process has been getting slower, as well as riskier and more costly. It generally takes 12–15 years from the initiation of ...